Mendoza RH, García AME

Language: Spanish
References: 21
Page: 165-171
PDF size: 64.17 Kb.

ABSTRACT

Osteoarthritis (OA) is the most expensive and most prevalent of articular diseases in adults. In 60 years and over adult populations, hip OA prevalence has a range of 17% in men and 9% in women. Hip OA has an important morbility, total hip replacement is frequently needed in 30-50% of patients after 10 years of disease. Different treatment options for OA have been analyzed including Pharmacological and non- pharmacological therapies. Among most prescribed drugs, non-steroid anti-inflammatory drugs (NSAIDs) are highlighted and are widely recommended by physicians in OA because it provides relief for mild and moderate symptoms. At present, alternative medical therapies are being developed based upon a better understanding of regulation of cartilage metabolism, directly involved in the pathogenesis of the disease. Nowadays knowledge points at the presence and actions of metalloproteases of the matrix. Other sources point at the evidence that cytokines IL-1B and the tumoral necrosis factor (TNF), represent the most important catabolic systems which are the most important sources of articular tissues degradation. Meloxicam is a derivate of enolic acid with good anti-inflammatory properties and tolerability profile. Diacerein is a purified compound with anthraquinone structure which has proven to inhibit in vivo and in vitro the production and activity of IL-1 and metalloproteases secretion without changing prostaglandins synthesis but exerting a remodeling mechanism of articular cartilage. Patients and methods. Clinical criteria to select patient: The presence of symptomatic disease defined as knee pain and/ or hip for at least one month, radiological inclusion criteria with articular space of 1-3 mm width. Results. 100 patients received the treatment (meloxicam/diacerein). After 60 days total patients (n = 50) of Group 1 continued with the treatment. Group 2, 48 patients continued the treatment. Main reason for exclusion was 2 patients did not fulfill with programmed appointments to “ visit 3”. Conclusions. Meloxicam/diacerein study demonstrated efficacy in controlling signs and symptoms: mobility and pain as well as a good tolerability profile.

REFERENCES

1. Dahms M, Lotz R, Lang W, Renner U, Bayer G, Spahn-Langguth H: Elucidation of phase I and phase II metabolic pathways of rhein: species differences and their potential relevance. Drug Metab Dispo 1997 25(4): 442-452.

2. Moore AR, Greenslade KJ, Alan CA, Willoughby DA: Effects of diacerein on granuloma induced cartilage breakdown in the mouse. Osteoarthritis Cartilage 1998; 6(1): 19-23.

3. Tamura T, Kasaka N, Ishiwa J, Sato T, Nagase H, I to A: Rhein, an active metabolite of diacerein, down-regulates the production of pro- matrix metallopreoteinases-1, -3. -9 and -13 and up regulates the production of tissue inhibitor of metalloproteinases-1 in cultures rabbit articular chondrocytes. Trauma Osteoarthritis Cartilage 2001; 9(3): 257-263.

4. Tamura T, Ohmari K: Rhein, an active metabolic of diacerein, suppresses the interleukin-1a-induced proteoglycan degradation in cultured rabbit articular chondrocytes. Jpn J Pharmacol 2001; 85(1): 101-104.

5. Ito A, Nose T, Takahashi S, Mori Y: Cyclooxygenase inhibitor augment the production of pro- matrix metalloproteinase 9 (progelatinase B) in rabbit articular chondrocytes. Lett 1995; 360(1): 75-79.

6. Yaron M, Shirazi I, Yaron I: Anti-interleukin-1 effects of diacerein and rhein in human osteoarthritic synovial tissue and cartilage cultures. Osteoarthritis Cartilage 1999; 7(3): 272-280.

7. Sanchez C, Mathy-Harter M, Deberg MA, Ficheux H, Reginster JY, Henrotin YE: Effects of rhein on human articular chondrocytes in alginate beads. Biochem Pharmacol 2003; 65(3): 377-388.

8. Tamura T, Ohmori K: Diacerein suppress the increase in plasma nitric oxide in rat adjuvant-induced arthritis. Eur J Pharmacol 2001; 419(2-3): 269-274.

9. Felisaz N, et al: Stimulating effect of diacerein on TGF-beta1 and beta2 expression in articular chondrocytes cultured with and without interleukin-1. Osteoarthritis Cartilage 1999; 7(3): 255-264.

10. Spencer CM: Diacerein. Drugs 1997; 53(1): 98-106, discussion 107-108.

11. Mendez AF: Diacerein and rhein prevent interleukin-1 beta- induced nuclear factor-Kappa b activation by inhibiting the degradation of inhibitor kappa b-alpha. Pharmacol Toxicol 2002; 91(1): 22-28.

12. Tamura T, Yokoyama T, Ohmori K: Effects of diacerein on indomethacion-induced gastric ulceration. Pharmacology 2001; 63(4): 228-233.

13. Pelletier JP, Mineau F, Boileau C, Martel-Pelletier J: Diacerein reduces the level of cartilage chondrocyte DNA fragmentation and death in experimental dog osteoarthritic cartilage at the time that it inhibits caspase-3 and inducible nitric oxid synthase. Clin Exp Rheumatol 2003; 21(2): 171-177.

14. Yaron M: Anti-interleukin-1 effects of diacerein and rhein in human osteoarthritic synovial tissue and cartilage cultures. Osteoarthritis Cartilage 1998; 7(3): 272-280.

15. Harrison: Dolor en la espalda y en el cuello. 13º edición. Principios de Medicina Interna. Editorial Panamericana Volumen 1 pp 83.

16. Bosch HC, Sigmund R, Hettich M: Efficacy and tolerability of intramuscular and oral Meloxicam in patients with acute lumbago: a comparison with intramuscular and oral piroxicam. Curr Med Res Opin 1997; 14(1): 29-38.

17. Engelhardt G, Boyel R, Schnitzler C, Utzmann R: Meloxicam influence on arachidonic acid. Metabolism. Part II. In vivo findings. Biochem Pharmacol 1996; 51(1): 29-38.

18. Lipscomb GR, Gallis N, Armstrong G, Rees WD: Gastrointestinal tolerability of meloxicam and piroxicam: a double-blind placebo-controlled study. Br J Pharmacol 1998; 46(2): 133-137.

19. Martindale: The Extra Pharmacopoeia. 31th edition pp 1017-1036.

20. Smith CM: Relajantes musculares. Farmacología Smith/Reynard. De. Panamericana 1993: 353-359.

21. Kellgren JH, Lawrence JS: Radiological assessment of osteoarthrosis. Ann Rheum Dis 1957; 16(4): 494-501.